Relationship between cardiac biomarker staging and outcome
| . | Stage I, 8 (23%) . | Stage II, 12 (34%) . | Stage III, 15 (43%) . | Log rank P . |
|---|---|---|---|---|
| Response | ||||
| No. of responders (%) | 6 (75) | 9 (82) | 6 (40) | |
| CR | 1 | 3 | 0 | |
| VGPR | 4 | 2 | 4 | |
| PR | 1 | 4 | 2 | |
| No. of cycles | 131 | 189 | 80 | |
| Median no. of mo on therapy (range) | 13 (3-39) | 13 (1-32) | 4 (1-17) | |
| Proportion of patients with at least 1 ≥ grade III toxicity (%) | 4 (50) | 10 (83) | 12 (80) | |
| Proportion of patients with at least 1 ≥ grade III nonhematologic toxicity (%) | 4 (50) | 9 (75) | 12 (80) | |
| Patients off for adverse event | 1 | 4 | 7 | |
| Died while on active therapy | 0 | 1 | 6 | |
| Survival | ||||
| Overall survival | ||||
| Median (95% CI) | NR | NR | 7 mo (4.6-12.3) | .0001 |
| No. of events | 0 | 2 | 12 | |
| PFS (hematologic or organ progression) | ||||
| Median (95% CI) | NR | 12.0 mo (1.6-NR) | 4.5 mo (1.1-6.5) | .004 |
| No. of events | 3 | 8 | 14 | |
| PFS (hematologic progression only) | ||||
| Median (95% CI) | NR | NR | 6.8 mo (4.2-28.3) | .005 |
| No. of events | 1 | 5 | 11 |
| . | Stage I, 8 (23%) . | Stage II, 12 (34%) . | Stage III, 15 (43%) . | Log rank P . |
|---|---|---|---|---|
| Response | ||||
| No. of responders (%) | 6 (75) | 9 (82) | 6 (40) | |
| CR | 1 | 3 | 0 | |
| VGPR | 4 | 2 | 4 | |
| PR | 1 | 4 | 2 | |
| No. of cycles | 131 | 189 | 80 | |
| Median no. of mo on therapy (range) | 13 (3-39) | 13 (1-32) | 4 (1-17) | |
| Proportion of patients with at least 1 ≥ grade III toxicity (%) | 4 (50) | 10 (83) | 12 (80) | |
| Proportion of patients with at least 1 ≥ grade III nonhematologic toxicity (%) | 4 (50) | 9 (75) | 12 (80) | |
| Patients off for adverse event | 1 | 4 | 7 | |
| Died while on active therapy | 0 | 1 | 6 | |
| Survival | ||||
| Overall survival | ||||
| Median (95% CI) | NR | NR | 7 mo (4.6-12.3) | .0001 |
| No. of events | 0 | 2 | 12 | |
| PFS (hematologic or organ progression) | ||||
| Median (95% CI) | NR | 12.0 mo (1.6-NR) | 4.5 mo (1.1-6.5) | .004 |
| No. of events | 3 | 8 | 14 | |
| PFS (hematologic progression only) | ||||
| Median (95% CI) | NR | NR | 6.8 mo (4.2-28.3) | .005 |
| No. of events | 1 | 5 | 11 |
PFS indicates progression-free survival; CI, confidence interval; and NR, not reached.